Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Pediatr Blood Cancer. 2019 Jun 28;66(10):e27905. doi: 10.1002/pbc.27905

FIGURE 2.

FIGURE 2

Trend of molecular and cytogenetic abnormalities; the left Y-axis represents the percentage of monosomy 7 and CDKN2A deletion by fluorescent in situ hybridization, and KRAS G12A variant allele fraction (VAF) by next-generation sequencing in bone marrow aspirates; the right Y-axis represents the percentage of aberrant B-cell lymphoblasts by flow cytometry; the X-axis denotes the time points during azacitidine (Aza) therapy at which that the molecular and cytogenetic data were obtained; BLD, below limit of detection